Evaxion A/S (NASDAQ:EVAX) Posts Quarterly Earnings Results, Misses Estimates By $0.43 EPS

Evaxion A/S (NASDAQ:EVAX) announced its earnings results on Thursday. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.43), Zacks reports.

Here are the key takeaways from Evaxion A/S’s conference call:

• EVX-01 phase II translational data showed a 86% immunogenicity rate with 86% de novo T cell responses, and the company expects to report 3‑year clinical outcome data in H2 2026.
• Evaxion demonstrated platform scalability to glioblastoma in collaboration with Duke—personalized vaccine designs were feasible for all 24 tumors, with 21/24 designs combining neoantigens and ERV antigens, supporting broader applicability beyond melanoma.
• In collaboration with the Gates Foundation, the company used AI‑Immunology to design a novel polio vaccine concept (hybrid capsid plus de novo T‑cell antigen), illustrating the platform’s ability to reinvent classical vaccines.
• Financial discipline preserved but runway is limited—cash and equivalents were $18.4M at quarter end, projected operational burn is roughly $14M for 2026, giving a runway into H2 2027 and implying potential need for financing absent partnerships.
• Management and business‑development changes include promotion of Birgitte Rønø to CSO/COO and addition of a BD‑focused board member, with multiple unspecified partnering discussions underway for both assets and the platform.

Evaxion A/S Stock Performance

Shares of NASDAQ:EVAX traded up $0.27 on Friday, reaching $4.34. 36,792 shares of the company’s stock were exchanged, compared to its average volume of 34,738. The firm has a market capitalization of $36.20 million, a price-to-earnings ratio of -2.95 and a beta of 0.26. Evaxion A/S has a fifty-two week low of $1.46 and a fifty-two week high of $12.15. The business’s 50-day moving average is $3.88 and its two-hundred day moving average is $4.56. The company has a quick ratio of 5.85, a current ratio of 5.85 and a debt-to-equity ratio of 0.41.

Institutional Trading of Evaxion A/S

An institutional investor recently bought a new position in Evaxion A/S stock. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 8,000 shares of the company’s stock, valued at approximately $38,000. Northwestern Mutual Wealth Management Co. owned 0.10% of Evaxion A/S as of its most recent SEC filing. 11.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts recently issued reports on EVAX shares. Lake Street Capital cut their price target on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Monday, March 9th. JonesTrading started coverage on shares of Evaxion A/S in a report on Tuesday, March 10th. They issued a “buy” rating and a $10.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. Wall Street Zen cut shares of Evaxion A/S from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Evaxion A/S in a report on Friday, April 24th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Evaxion A/S presently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.